Bracken

Learn more about the skills and expertise our team can bring to your life science orginazation. We asked Brad Wyman, MS, PhD, Senior Partner how his background as a research science and in biomedical engineering has informed his executive roles, decision-making, and approach to consulting. He had this to say: "I'd like to make a distinction between being a scientist and what I consider myself to be—which is an engineer. The distinction is that a scientist will take a toaster apart to see how it works, whereas the engineer will take it apart to see how to fix it. And every project I've been involved in, I've wanted to know: what would be the impact if the work continued? Why are we doing this? Why should we move forward?" #ClinicalResearch #LifeSci

Critical Imaging Risks in GLP-1 & Neurology Studies: What You Need to Know Join the webinar discussion on April 3rd to explore early indicators of imaging challenges, preclinical insights, therapeutic area trends, hidden risks in trial imaging, and more. ?? Reserve your spot for the discussion: https://lnkd.in/egaQNJcE ??? Speakers: Jessica McKenzie, Vice President, Life Sciences, 20/20 Onsite Dr. David Nguyen, MD, MBA, General Manager and Medical Director, Altasciences Dr. Simone Iwabe, DVM, PhD, DACVO, Senior Veterinary Ophthalmologist, Altasciences Dr. Colin Miller, PhD, FIPEM, CSci, Founder, Bracken

We created a GTM strategy to enable a global biopharmaceutical and clinical manufacturing company to expand its operations into the U.S. Market. The results speak for themselves: - 96 high-quality leads generated. - A 133.8%+ increase in LinkedIn post impressions and 2,047 post engagements. - 95% increase in page views driven to a promoted blog. Find out more about the necessity of a comprehensive marketing strategy, as well as the scenario, challenge, strategy, and results here: https://hubs.la/Q038mSlq0 #LeadGen #Pharma

?? Conducting GLP-1 or Neurology Trials? Don't let imaging risks derail your study! Join Colin Miller, CEO of Bracken, on April 3rd at 11 AM ET for a must-attend webinar hosted by 20/20 Onsite & Clinical Leader: Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to Know. Learn how to: ? Identify imaging pitfalls before they cause costly delays ? Use preclinical insights to strengthen trial outcomes ? Navigate complex imaging regulations with confidence Register now! https://lnkd.in/g6g2exVh #ClinicalTrials #MedicalImaging #GLP1 #Neurology #DrugDevelopment #Bracken

Do you know your NDA from your CTAs? What about your CTRs from your KPIs? The life science marketing industry is full of acronyms and jargon, but we're here to demystify the lingo. Our blog explains the meaning behind some of the most commonly used marketing and advertising terms so you're always speaking the same life science language: https://hubs.la/Q038mPvS0 #Marketing #LifeSci

Register for the 20/20 Onsite + Clinical Leader webinar now! Join Bracken CEO Colin Miller, PhD, FIPEM, CSci and fellow industry experts on April 3rd at 11 AM ET as they present: Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to Know. Colin brings decades of expertise in medical imaging and clinical trials—don’t miss this chance to gain insider knowledge on avoiding imaging pitfalls, reducing late-phase risks, and navigating evolving trial requirements. ?? Reserve your spot today: https://lnkd.in/g6g2exVh #ClinicalTrials #MedicalImaging #GLP1 #Neurology #DrugDevelopment #Bracken

The FDA has long prioritized and incentivized research into new antibiotics. While drugmakers still struggle to sell them due to well-established financial challenges, there have been a series of approvals in recent years. The agency approved a new combination antibiotic developed by AbbVie and Pfizer for tough-to-treat bacterial infections at the beginning of February. Find out more about Emblaveo, which is expected to be available in the U.S. by the third quarter: https://hubs.la/Q038mT5T0 #DrugDev #Pharma

With the first 10 drugs already negotiated under the Inflation Reduction Act’s (IRA) drug pricing provisions slated to go into effect next year, the law has already become status quo, according to one industry expert. Phil Sclafani, a principal at PwC US, said, We’ve seen an attitude of, ‘OK, the IRA is here — we’re going to keep the drugs that were selected, and we’re going to negotiate in good faith and go forward.’” But, with a new administration in the White House, things could be set to change. This article looks at the short- and long-term future of the IRA and its impact on pharma: https://hubs.la/Q038mSlr0 #DrugDev #Pharma

The FDA has rolled out several new and updated guidance since the start of the year. This guidance covers topics such as: - Developing drugs for optical imaging - Revised guidance on weight management products - Lead levels in processed food intended for babies and young children - Tissue biopsies in clinical trials The breadth of these updates reflects the FDA’s ongoing efforts to enhance regulatory clarity and ensure public health safety across various sectors. Read our summary of the guidance in this article and access links to the documents in full: https://hubs.la/Q038mH940 #FDA #Compliance

?? Exciting News! Bracken’s own Colin Miller, PhD, FIPEM, CSci will be a featured speaker at the upcoming webinar: Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to Know. ?? April 3 | 11 AM EST ??Hosted by Clinical Leader Don't miss this opportunity to hear from industry experts on overcoming hurdles in medical imaging for GLP-1 and neurology studies. ?? Register now and secure your spot: #Webinar #MedicalImaging #Neurology #GLP1 #BrackenExperts